An Island company that's helping veterinarians reduce use of antibiotics has announced a major private investment deal that will enable it to scale up production, and market its Island-made health products worldwide.
MicroSintesis has closed a deal worth $16.4 million with Toronto-based Northern Private Capital.
"The world is focused on antibiotic resistance ... so we're looking to take our technology to global markets," said Hannah McIver, CEO and founder of MicroSintesis. "We're looking to build what will be a first-in-class production facility."
Image: MicroSintesis says it will expand production facilities, among other initiatives, as a result of a new $16.4 million private investment. (Brian Higgins/CBC)
